What the Cannabis Investor Pool Looks Like Right Now
Cannabis is a small, specific slice of the AngelMatch database, and that is actually useful information. The 490+ investors tagged to cannabis are close to evenly split among three groups: private equity investors, venture capital investors, and angel investors, with private equity investors holding a slight edge. That balance tells you something founders in bigger markets do not get to know so precisely: if you strike out with venture funds, there is a real bench of private equity and angel money still to work through, not just a long tail of generalists who will never say yes.
The category is also still shaped by federal law in a way most markets on this site are not. Cannabis remains illegal at the federal level, but 24 states plus Washington DC now allow adult-use retail sales as of 2026, according to MJBizDaily's state-by-state tracker. That state map matters more to a cannabis investor than it would to almost any other market you could pitch, because it defines where a company can legally operate, bank, and sell in the first place.
Where Cannabis Investors Are Based
Roughly two out of three cannabis investors in the database are based in the United States, and within the US the pool is lopsided even further. California and New York alone account for more cannabis investors than the rest of the country combined, which lines up with how the industry actually built out: California as the largest legal cultivation and retail market, New York as a finance and brand hub that came online later but moved fast. Florida, Texas, Massachusetts, and Illinois round out the next tier, each with a modest but real cluster.
Outside the US, Canada and France have the largest pools of cannabis investors on the platform, which tracks with their histories. Canada legalized adult-use cannabis nationwide in 2018 and built a public capital markets ecosystem around it years before most US states caught up, so it still has a deeper bench of specialist funds. France's presence is smaller in absolute terms but notable given how restrictive French cannabis law remains, and likely reflects investors positioned for a market that has not opened yet rather than one that has. Germany, Switzerland, and the UK each have a handful of active investors too, mostly tied to Europe's slower-moving medical and CBD markets.
Back in the US, the tier below California and New York tells its own story. Massachusetts has built a durable medical and adult-use market with strong local demand, and its investor cluster reflects that. Illinois pairs a large adult-use market with an active social equity licensing program, which has drawn a specific type of investor interested in operators building around those licenses. Florida and Texas both show up mainly through medical programs rather than adult-use retail, and Connecticut's small but present cluster is a reminder that even newer, smaller adult-use states can attract early money once the state passes a workable regulatory framework. If your company operates in one of these secondary states, do not assume you need a California or New York investor to get funded. Plenty of the capital in this database is intentionally regional.
What Cannabis Investors Are Actually Funding
Capital in cannabis has not spread evenly across the supply chain, and knowing where the money has concentrated helps you frame your pitch. In the twelve months ending April 2025, Cultivation and Retail was the most active sector for M&A activity in US cannabis, with $589.9 million in total deal consideration, according to Viridian Capital Advisors' deal tracking. Infused Products and Extracts ranked second at $421.1 million, driven largely by branded, hemp-derived products competing for shelf space. That second category is worth paying attention to if you are building a consumer brand rather than a cultivation or retail operation, since it is where a lot of the differentiation and deal activity is actually happening.
A meaningful share of the investors in this database also show up tagged to health care, wellness, and biotech markets elsewhere on the platform. That crossover is not a coincidence. Many of the generalist and specialist funds willing to touch cannabis are doing so through a wellness or biotech lens, backing cannabinoid-based therapeutics, functional wellness brands, or agtech for cultivation, rather than writing checks purely on the strength of a dispensary rollout. If your company has a genuine health, wellness, or life-science angle, it is worth leading with that framing for investors who are still cautious about plant-touching risk on its own.
Which Funding Stage Actually Fits You
The stage breakdown among cannabis investors skews heavily toward the earliest rounds. Seed is the single largest stage tag in the database, followed by early stage venture, with series A, series B, and pre-seed each making up a smaller slice, and late stage venture money is genuinely scarce. That shape is not an accident. Cannabis companies still face federal banking limits, high effective tax rates under 280E, and state-by-state licensing costs that eat into growth capital, so a lot of institutional money that would normally show up at series B and beyond simply is not chasing plant-touching deals yet. If you are raising a seed or early stage round, you have real company. If you are further along and hunting for a growth round, expect a smaller, more selective pool and budget more time for outreach.
This also changes how you should read a "no." In most markets, getting passed on at series A means your metrics or market size did not clear the bar. In cannabis, it is just as often a fund-level decision that the partner does not do plant-touching deals at all, regardless of how strong your numbers are. Ask directly, early in the conversation, whether an investor's fund has a cannabis carve-out or restriction. It saves both sides time and tells you whether to keep pursuing a check size and stage that otherwise looks like a fit.
What It Costs to Raise, and What Cannabis Investors Expect
The check sizes in cannabis follow the same ranges as the rest of the market. Angel investors typically write checks between $25,000 and $500,000, while venture checks run from $2 million up to $100 million or more at the largest funds, and early rounds usually give up somewhere around 15% to 25% of the company. What is different in cannabis is what investors dig into before they get anywhere near a term sheet.
Section 280E of the federal tax code blocks cannabis businesses from deducting most ordinary expenses, which compresses margins in a way investors from other industries are not used to modeling. Expect diligence questions about your effective tax rate, not just your gross margin. Banking access is the other recurring friction point: many mainstream banks still avoid cannabis accounts outright, so investors will want to know who holds your deposits and how you move money, since a banking relationship that falls apart mid-runway is a real operational risk, not a hypothetical one. On top of that, several of the larger multi-state operators are carrying meaningful debt that comes due in 2026, which has made some investors more selective about which parts of the sector they will fund with fresh equity right now.
How to Approach Cannabis Investors
Lead with your state footprint, not your total addressable market. A cannabis investor's first question is usually which states you are licensed in and which you plan to enter next, because that answer tells them your realistic revenue path far better than a national market-size slide does. If you only operate in one or two states, say so plainly and explain your expansion order rather than burying it.
Be ready to talk about your margin story under 280E specifically, since generic startup financial models that assume normal expense deductions will read as a red flag to anyone who has funded cannabis companies before. And if your business has a wellness, biotech, or agtech thread alongside the plant-touching side, put that up front. It widens your investor pool to funds that are comfortable with the underlying science or consumer category but still cautious about federal cannabis risk on its own.
Cannabis investing still runs on relationships built state by state, so the fastest way to narrow this list is to filter for investors active in the states where you are actually licensed or plan to launch first. Once you have a shortlist, keep every cannabis investor conversation in one place instead of a scattered inbox, which is where a tool like Fundraising CRM earns its keep. Check back on this list every few months too, since cannabis investor rosters shift faster than most sectors as generalist funds move in and out of the space.
Health care investors
